Table 3. Multivariate analysis of grades... | American Society of Hematology

Table 3.

Multivariate analysis of grades II to IV acute GVHD

	Relative risk of grades II to IV acute GVHD (95% CI)	P
HLA-identical sibling BM
G-CSF⁺ within 7 days after transplantation vs no G-CSF^*	1.11 (0.86-1.42)	.42
Age	1.02 (1.01-1.03)	.001
KPS more than 80^* vs less than 80%	1.62 (1.28-2.03)	.001
TBI vs no TBI^*	1.40 (1.12-1.74)	.003
CML vs AML^*	1.29 (1.04-2.58)	.002
HLA-identical sibling PBSCs
G-CSF⁺ within 7 days after transplantation vs no G-CSF^*	1.21 (0.95-1.62)	.11
Matched unrelated donor BM
G-CSF⁺ within 7 days after transplantation vs no G-CSF^*	0.83 (1.07-1.72)	.10
CML vs AML^*	1.35 (1.07-1.72)	.01

	Relative risk of grades II to IV acute GVHD (95% CI)	P
HLA-identical sibling BM
G-CSF⁺ within 7 days after transplantation vs no G-CSF^*	1.11 (0.86-1.42)	.42
Age	1.02 (1.01-1.03)	.001
KPS more than 80^* vs less than 80%	1.62 (1.28-2.03)	.001
TBI vs no TBI^*	1.40 (1.12-1.74)	.003
CML vs AML^*	1.29 (1.04-2.58)	.002
HLA-identical sibling PBSCs
G-CSF⁺ within 7 days after transplantation vs no G-CSF^*	1.21 (0.95-1.62)	.11
Matched unrelated donor BM
G-CSF⁺ within 7 days after transplantation vs no G-CSF^*	0.83 (1.07-1.72)	.10
CML vs AML^*	1.35 (1.07-1.72)	.01

BM indicates bone marrow; G-CSF, granulocyte colony-stimulating factor; KPS, Karnofsky performance status; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; and PBSC, peripheral blood stem cell.

Reference group

View Large

This Feature Is Available To Subscribers Only